The Indian pharmaceutical sector experienced a decline on March 12, 2026, with most listed stocks trading lower in early morning sessions.
The S&P BSE HEALTHCARE Index stood at 43,421.7, down 1.2% at the time of the update. This compared to the broader market, where the S&P BSE SENSEX was at 76,041.26 (down 1.07%) and the Nifty 50 was at 23,592.65 (down 1.15%).
Key Stock Performance (as of approximately 9:33-9:34 AM IST)
- Most pharma stocks showed declines on both BSE and NSE.
- Notable examples:
-
Aarti Drugs: BSE ₹348.65 (-1.26%), NSE ₹347.95 (-1.36%)
- Abbott India: BSE ₹26,780.65 (-1.58%), NSE ₹26,790.00 (-1.51%)
- Divi’s Laboratories: BSE ₹6,260.00 (-1.40%), NSE ₹6,234.00 (-1.87%)
- Sun Pharma: BSE ₹1,819.30 (-0.31%), NSE ₹1,818.70 (-0.39%)
- Aurobindo Pharma was one of the few with gains: BSE ₹1,310.10 (+0.42%), NSE ₹1,306.30 (+0.11%)
- IPCA Labs: BSE ₹1,549.10 (+1.10%), NSE ₹1,537.60 (+0.24%)
-
A small number of stocks posted gains or minimal changes, but the majority closed lower.
Broader Context
The pharma sector was down alongside the overall market, which saw pressure from factors such as geopolitical tensions, crude oil volatility, and global cues in early March 2026. The BSE HEALTHCARE Index had gained 1.9% over the prior 30 days and 10.8% over the last year, indicating the daily move was part of short-term volatility rather than a longer-term reversal.
Top gainers in the broader pharmaceuticals space included Aspira Pathlab & Diagnostics (up 12.4%) and Medi Caps (up 10.2%), while losers included Dipna Pharmachem (down 7.8%) and Link Pharma (down 5.9%).
This update reflects intraday prices from March 12, 2026, around 9:30-9:35 AM IST. Stock movements can change throughout the trading day based on market conditions.